Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Biological: G17DT-Irinotecan
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Cancer Advances Inc.
- Target Recruit Count
- 161
- Registration Number
- NCT02118064
An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Cancer Advances Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02098291
Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Cancer Advances Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT02098239
Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma
Phase 3
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- Biological: G17DT Immunogen
- First Posted Date
- 2002-08-20
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Cancer Advances Inc.
- Target Recruit Count
- 394
- Registration Number
- NCT00044031
Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer
Phase 2
Completed
- Conditions
- Stomach NeoplasmsEsophageal Neoplasms
- Interventions
- Biological: Treatment group
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2014-08-28
- Lead Sponsor
- Cancer Advances Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT00042510
© Copyright 2025. All Rights Reserved by MedPath